Data

This subtopic contains guidance on EU level rules relating to non-personal data.

On 19 February 2020, the Commission published a ‘European Strategy for data’ with the aim to create a single market for data which will make the EU more competitive globally and will enable innovative processes, products and services. EU data initiatives include the EU Data Governance Act, the EU Data Act, the EU Open Data Directive, and access to in-vehicle data. It further includes Common European Data Spaces such as the European Health Data Space, and the European Mobility Data Space.

Tracking developments

Practice Note: EU data initiatives—tracker tracks the progress or implementation of the following initiatives:

  1. EU Data Governance Act

  2. EU Data Act

  3. EU Open Data Directive

  4. European Health Data Space

  5. European Mobility Data Space

  6. European Tourism Data Space

  7. European Green Deal Data Space

  8. Access to vehicle data, and

  9. Data collection

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents